Xencor Q3 net loss $32.8M ($0.55/sh); XmAb564 shows durable Treg expansion in Phase 1a

Xencor Inc

2022-Q3 EPS reported -$0.72 revenue$142,969,000

Q3 revenue $27.3M (up from $19.7M); net loss $32.8M vs $40.2M loss year ago.
Cash $654.6M; funding through 2025; year-end 2022 cash guided at $575-600M.
XmAb564 Phase 1a: single-dose well-tolerated; 117-fold peak CD25 bright Treg expansion; Phase 1b in atopic dermatitis/psoriasis started.
Vudalimab Phase 2 in mCRPC; plamotamab Phase 2 enrolling; data at SITC and ASH.
Vir royalty $17.8M in Q3; Zenas raised $118M, plans Phase 3 for obexelimab.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Xencor Inc reported financial results for the quarter ended September 30, 2022.

Period: the quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 7, 2022, Xencor, Inc. announced its financial results for the quarter ended September 30, 2022 in the press release attached hereto as Exhibit 99.1

View on SEC.gov

Browse all earnings releases →

Xencor Inc filing history →

Source: SEC EDGAR

accession 0001558370-22-016645

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.